Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
2022 · The Lancet · 391 citations
https://doi.org/10.1016/s0140-6736(22)02597-1